Home
HelpTest Code P2PHI [-2]Pro Prostate-Specific Antigen with Prostate Health Index, Serum
Specimen Required
Patient Preparation:
1. Specimens for testing should be collected prior to prostate manipulations such as digital rectal examination (DRE), prostatic massage, transrectal ultrasound (TRUS), and prostatic biopsy.
2. A 6-week waiting period between needle biopsy and specimen collection is recommended.
3. Specimens should not be collected from patients receiving therapy with high biotin (vitamin B7) doses (ie, >5 mg/day) until at least 8 hours following the last biotin administration.
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Within 3 hours of collection, centrifuge, aliquot serum into a plastic vial, and refrigerate. Freeze sample within 24 hours of collection and send frozen.
Useful For
As an aid in distinguishing prostate cancer from benign prostatic conditions in men aged 50 years and older with total PSA between 4.0 and 10.0 ng/mL and digital rectal examination findings that are not suspicious for cancer.
Method Name
Immunoenzymatic Assay
Reporting Name
p2PSA with Prostate Health Index, SSpecimen Type
Serum RedSpecimen Minimum Volume
0.75 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum Red | Frozen (preferred) | 150 days | |
| Ambient | 24 hours | ||
| Refrigerated | 24 hours |
Reference Values
Females: Not applicable
PROSTATE-SPECIFIC ANTIGEN (PSA) MALES:
|
Age |
Reference range |
|
<40 Years |
≤2.0 ng/mL |
|
40-49 Years |
≤2.5 ng/mL |
|
50-59 Years |
≤3.5 ng/mL |
|
60-69 Years |
≤4.5 ng/mL |
|
70-79 Years |
≤6.5 ng/mL |
|
≥80 Years |
≤7.2 ng/mL |
PERCENT FREE PSA MALES:
When total PSA is in the range of 4-10 ng/mL
|
% Free PSA |
Probability of cancer |
|
≤10% |
56% |
|
11-15% |
28% |
|
16-20% |
20% |
|
21-25% |
16% |
|
>25% |
8% |
PROSTATE HEALTH INDEX (phi) MALES:
When PSA is in the range of 4-10 ng/mL
|
phi range |
Probability of cancer |
95% Confidence interval |
|
0-26.9 |
9.8% |
5.2-15.4% |
|
27.0-35.9 |
16.8% |
11.3-22.2% |
|
36.0-54.9 |
33.3% |
26.8-39.9% |
|
≥55.0 |
50.1% |
39.8-61.0% |
Interpretation
The prostate health index (phi) may be used to determine the probability of prostate cancer on biopsy in men 50 years of age and older with total prostate-specific antigen (PSA) in the 4.0 to 10.0 ng/mL range. Low phi scores are associated with a lower probability of finding prostate cancer on biopsy, and higher phi scores are associated with an increased probability of finding prostate cancer on biopsy. The choice of an appropriate phi score to be used in guiding clinical decision making may vary for each patient and may depend on other clinical factors or family history. The table below indicates the probability of finding prostate cancer on biopsy when total PSA is in the range of 4.0 to 10.0 ng/mL and may be used as guidance for interpreting the phi score.
|
phi range |
Probability of cancer |
95% Confidence interval |
|
0-26.9 |
9.8% |
5.2%-15.4% |
|
27.0-35.9 |
16.8% |
11.3%-22.2% |
|
36.0-54.9 |
33.3% |
26.8%-39.9% |
|
55.0+ |
50.1% |
39.8%-61.0% |
Clinical Reference
1. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate-specific antigen combined with prostate-specific antigen and free prostate-specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate-specific antigen range. J Urology. 2011;185:1650-1655
2. Pecoraro V, Roli L, Plebani M, Trenti T. Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review. Clin Chem Lab Med. 2016;54(7):1123-1132. doi:10.1515/cclm-2015-0876
3. Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014;6(2):74-77 doi:10.1177/1756287213513488
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
84153-Total PSA
84154-Free PSA
86316-[-2]ProPSA
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| P2PHI | p2PSA with Prostate Health Index, S | 53764-7 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| PSAT | Prostate Specific Antigen, S | 83112-3 |
| PSAF | Free PSA, S | 83113-1 |
| PSAP2 | [-2]ProPSA, S | 97149-9 |
| PSAP3 | % Free PSA | 12841-3 |
| PSAP4 | Prostate Health Index | 97150-7 |
Day(s) Performed
Monday through Saturday